| pubmed-article:2279254 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2279254 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2279254 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:2279254 | lifeskim:mentions | umls-concept:C0011854 | lld:lifeskim |
| pubmed-article:2279254 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:2279254 | lifeskim:mentions | umls-concept:C0021655 | lld:lifeskim |
| pubmed-article:2279254 | lifeskim:mentions | umls-concept:C0123043 | lld:lifeskim |
| pubmed-article:2279254 | pubmed:dateCreated | 1991-3-8 | lld:pubmed |
| pubmed-article:2279254 | pubmed:abstractText | Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol, HDL-cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type I diabetic patients. | lld:pubmed |
| pubmed-article:2279254 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2279254 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2279254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2279254 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2279254 | pubmed:issn | 0008-6312 | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:CicchettiVV | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:NavalesiRR | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:CecchettiPP | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:BenziLL | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:CiccaroneA... | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:Di CianniGG | lld:pubmed |
| pubmed-article:2279254 | pubmed:author | pubmed-author:SabinoFF | lld:pubmed |
| pubmed-article:2279254 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2279254 | pubmed:volume | 77 Suppl 5 | lld:pubmed |
| pubmed-article:2279254 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2279254 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2279254 | pubmed:pagination | 63-6 | lld:pubmed |
| pubmed-article:2279254 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:meshHeading | pubmed-meshheading:2279254-... | lld:pubmed |
| pubmed-article:2279254 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2279254 | pubmed:articleTitle | Ibopamine does not affect insulin resistance in patients with type I diabetes. | lld:pubmed |
| pubmed-article:2279254 | pubmed:affiliation | Chair of Metabolic Disease, University of Pisa, Italy. | lld:pubmed |
| pubmed-article:2279254 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2279254 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2279254 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
